CBLL
VENTE TOTALE: 131 317 titres (~2 981 028,21 $ US)
- Insiders
- Chao Xingjuan, Taylor Joseph Michael
- Total bought
- —
- Total sold
- $2,981,028
- Last activity
- 2026-09-02
- Last synced
-
2026-09-08 09:54:45
Insider holdings as a share of total assets aren't available for this company.
Price (1 year)
Live chart from TradingView - pulls its own market data, independent of this site's database. Symbol resolution is best-effort (defaults to NASDAQ) since we don't store the exchange prefix.
Market snapshot
Signal
Bearish signal Scored 2026-09-08
CBLL presents a mixed picture where a moderate earnings catalyst (33% revenue growth, FDA clearance, institutional accumulation by BlackRock and BofA) is significantly undermined by severe underlying financial distress…
The first sentence of the analysis written for CBLL on 2026-09-08 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Gross Profit Margin | 87.9% | 86.7% | 84.4% | 82.9% | |
| Ebit Margin | -57.8% | -58.8% | -60.5% | -137.2% | |
| Ebitda Margin | -56.3% | -57.0% | -58.6% | -135.3% | |
| Operating Profit Margin | -65.6% | -60.7% | -66.4% | -139.0% | |
| Pretax Profit Margin | -60.0% | -61.8% | -65.1% | -143.4% | |
| Continuous Operations Profit Margin | -60.0% | -61.8% | -65.1% | -143.4% | |
| Net Profit Margin | -60.0% | -61.8% | -65.1% | -143.4% | |
| Bottom Line Profit Margin | -60.0% | -61.8% | -65.1% | -143.4% | |
| Current Ratio | 9.730 | 16.727 | 2.406 | 8.090 | |
| Quick Ratio | 9.350 | 16.193 | 2.134 | 7.677 | |
| Solvency Ratio | -1.287 | -1.148 | -0.167 | -0.212 | |
| Cash Ratio | 2.109 | 14.964 | 1.597 | 6.918 | |
| Price To Earnings Ratio | -15.021 | -22.903 | -19.841 | -15.723 | |
| Price To Earnings Growth Ratio | -0.514 | 2.220 | 0.956 | 0.000 | |
| Forward Price To Earnings Growth Ratio | -0.514 | 2.220 | 0.956 | 0.000 | |
| Price To Earnings Diluted Ratio | -15.021 | -22.903 | -19.841 | -15.723 | |
| Price To Earnings Diluted Growth Ratio | -0.514 | 2.220 | 0.956 | 0.000 | |
| Price To Book Ratio | 5.159 | 4.853 | -5.195 | -6.749 | |
| Price To Sales Ratio | 8.998 | 14.177 | 12.893 | 22.495 | |
| Price To Free Cash Flow Ratio | -19.275 | -25.501 | -19.345 | -17.932 | |
| Price To Operating Cash Flow Ratio | -19.638 | -26.476 | -19.997 | -18.221 | |
| Debt To Assets Ratio | 0.114 | 0.097 | 0.241 | 0.211 | |
| Debt To Equity Ratio | 0.143 | 0.115 | -0.127 | -0.211 | |
| Debt To Capital Ratio | 0.125 | 0.103 | -0.145 | -0.267 | |
| Long Term Debt To Capital Ratio | 0.113 | 0.093 | 0.000 | -0.173 | |
| Financial Leverage Ratio | 1.261 | 1.179 | -0.525 | -1.001 | |
| Working Capital Turnover Ratio | 0.479 | 0.558 | 0.902 | 0.000 | |
| Operating Cash Flow Ratio | -2.127 | -2.698 | -1.350 | -3.244 | |
| Operating Cash Flow Sales Ratio | -0.458 | -0.535 | -0.645 | -1.235 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.019 | 1.038 | 1.034 | 1.016 | |
| Debt Service Coverage Ratio | -26.551 | -18.736 | -1.904 | -8.546 | |
| Interest Coverage Ratio | -30.901 | -19.934 | -14.319 | -22.471 | |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | -2.464 | -12.801 | |
| Operating Cash Flow Coverage Ratio | -1.832 | -1.596 | -2.053 | -1.756 | |
| Capital Expenditure Coverage Ratio | -53.205 | -26.151 | -29.663 | -62.019 | |
| Dividend Paid And Capex Coverage Ratio | -53.205 | -26.151 | -29.663 | -62.019 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -15.607 | -20.240 | -21.232 | -15.204 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 87.9% | ▲1.2% | ▲2.4% |
| Ebit Margin | -57.9% | ▲0.9% | ▲20.7% |
| Ebitda Margin | -56.3% | ▲0.7% | ▲20.5% |
| Operating Profit Margin | -65.6% | ▼-4.9% | ▲17.3% |
| Pretax Profit Margin | -60.0% | ▲1.8% | ▲22.6% |
| Continuous Operations Profit Margin | -60.0% | ▲1.8% | ▲22.6% |
| Net Profit Margin | -60.0% | ▲1.8% | ▲22.6% |
| Bottom Line Profit Margin | -60.0% | ▲1.8% | ▲22.6% |
| Current Ratio | 9.730 | ▼-6.997 | ▲0.492 |
| Quick Ratio | 9.350 | ▼-6.843 | ▲0.512 |
| Solvency Ratio | -1.287 | ▼-0.139 | ▼-0.583 |
| Cash Ratio | 2.109 | ▼-12.855 | ▼-4.288 |
| Price To Earnings Ratio | -15.021 | ▲7.882 | ▲3.351 |
| Price To Earnings Growth Ratio | -0.514 | ▼-2.734 | ▼-1.180 |
| Forward Price To Earnings Growth Ratio | -0.514 | ▼-2.734 | ▼-1.180 |
| Price To Earnings Diluted Ratio | -15.021 | ▲7.882 | ▲3.351 |
| Price To Earnings Diluted Growth Ratio | -0.514 | ▼-2.734 | ▼-1.180 |
| Price To Book Ratio | 5.159 | ▲0.305 | ▲5.642 |
| Price To Sales Ratio | 8.998 | ▼-5.179 | ▼-5.643 |
| Price To Free Cash Flow Ratio | -19.275 | ▲6.226 | ▲1.238 |
| Price To Operating Cash Flow Ratio | -19.637 | ▲6.839 | ▲1.446 |
| Debt To Assets Ratio | 0.114 | ▲0.016 | ▼-0.052 |
| Debt To Equity Ratio | 0.143 | ▲0.029 | ▲0.163 |
| Debt To Capital Ratio | 0.125 | ▲0.022 | ▲0.171 |
| Long Term Debt To Capital Ratio | 0.113 | ▲0.020 | ▲0.105 |
| Financial Leverage Ratio | 1.260 | ▲0.081 | ▲1.032 |
| Working Capital Turnover Ratio | 0.479 | ▼-0.079 | ▼-0.006 |
| Operating Cash Flow Ratio | -2.127 | ▲0.571 | ▲0.228 |
| Operating Cash Flow Sales Ratio | -0.458 | ▲0.077 | ▲0.260 |
| Free Cash Flow Operating Cash Flow Ratio | 1.019 | ▼-0.019 | ▼-0.008 |
| Debt Service Coverage Ratio | -26.551 | ▼-7.815 | ▼-12.617 |
| Interest Coverage Ratio | -30.901 | ▼-10.966 | ▼-8.994 |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | ▲3.816 |
| Operating Cash Flow Coverage Ratio | -1.832 | ▼-0.236 | ▼-0.023 |
| Capital Expenditure Coverage Ratio | -53.205 | ▼-27.053 | ▼-10.445 |
| Dividend Paid And Capex Coverage Ratio | -53.205 | ▼-27.053 | ▼-10.445 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -15.607 | ▲4.633 | ▲2.464 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Market cap | $801.4M | $927.8M | $583.1M | $583.1M | |
| Enterprise value | $783.2M | $755.4M | $562.8M | $533.1M | |
| EV / Sales | 8.79x | 11.54x | 12.45x | 20.57x | |
| EV / Op. cash flow | -19.19x | -21.56x | -19.30x | -16.66x | |
| EV / Free cash flow | -18.84x | -20.76x | -18.67x | -16.39x | |
| EV / EBITDA | -15.61x | -20.24x | -21.23x | -15.20x | |
| Net debt / EBITDA | 0.36x | 4.62x | 0.77x | 1.43x | |
| Current ratio | 9.73x | 16.73x | 2.41x | 8.09x | |
| Income quality | 0.76x | 0.87x | 0.99x | 0.86x | |
| Graham net-net | $4 | $5 | -$5 | -$4 | |
| Tax burden | 100.0% | 100.0% | 100.0% | 100.0% | |
| Interest burden | 103.7% | 105.2% | 107.7% | 104.5% | |
| Working capital | $167.5M | $204.3M | $30.4M | $69.9M | |
| Invested capital | $172.7M | $208.7M | $34.1M | $73.8M | |
| Return on assets | -27.3% | -17.9% | -50.0% | -43.0% | |
| Operating ROA | -27.7% | -27.9% | -41.3% | 0.0% | |
| Return on tangible assets | -27.4% | -17.9% | -50.0% | -43.0% | |
| Return on equity | -34.4% | -21.2% | 26.2% | 43.0% | |
| Return on invested capital | -32.9% | -18.6% | -60.3% | -45.2% | |
| Return on capital employed | -33.1% | -18.7% | -80.5% | -47.0% | |
| Earnings yield | -6.7% | -4.4% | -5.1% | -6.4% | |
| Free cash flow yield | -5.2% | -3.9% | -5.2% | -5.6% | |
| Capex / Op. cash flow | -1.9% | -3.8% | -3.4% | -1.6% | |
| Capex / Depreciation | -114.5% | 117.4% | 116.1% | 103.8% | |
| Capex / Sales | 0.9% | 2.0% | 2.2% | 2.0% | |
| SG&A / Sales | 132.0% | 126.7% | 130.9% | 193.9% | |
| R&D / Sales | 21.5% | 20.7% | 19.9% | 27.9% | |
| Stock comp / Sales | 13.7% | 8.3% | 5.9% | 30.6% | |
| Intangibles / Total assets | 0.4% | 0.0% | 0.0% | 0.0% | |
| Days sales outstanding | 62d | 61d | 64d | 75d | |
| Days payables outstanding | 96d | 48d | 38d | 35d | |
| Operating cycle | 308d | 352d | 367d | 410d | |
| Cash conversion cycle | 212d | 304d | 330d | 375d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▼-13.6%EV / Sales ▼-23.8%EV / EBITDA ▲+22.9%EV / Op. cash flow ▲+2.365Earnings yield ▼-0.023
Profitability
Return on equity ▼-0.132Return on assets ▼-0.093Return on invested capital ▼-0.143Return on capital employed ▼-0.144Operating ROA ▲+0.002Income quality ▼-0.102Tax burden 0.000
Efficiency
Days sales outstanding ▲+1.021Days payables outstanding ▲+48.025Operating cycle ▼-43.657Cash conversion cycle ▼-91.682Capex / Sales ▼-0.012R&D / Sales ▲+0.008
Balance-sheet strength
Current ratio ▼-6.997Net debt / EBITDA ▼-4.257Working capital ▼-36755000.000Invested capital ▼-36069000.000Intangibles / Total assets n/a
Change over 5 years
Valuation
Market cap ▲+37.4%EV / Sales ▼-57.2%EV / EBITDA ▼-2.6%EV / Op. cash flow ▼-2.533Earnings yield ▼-0.003
Profitability
Return on equity ▼-0.774Return on assets ▲+0.157Return on invested capital ▲+0.123Return on capital employed ▲+0.140Operating ROA n/aIncome quality ▼-0.097Tax burden -0.000
Efficiency
Days sales outstanding ▼-12.867Days payables outstanding ▲+61.160Operating cycle ▼-102.059Cash conversion cycle ▼-163.218Capex / Sales ▼-0.011R&D / Sales ▼-0.064
Balance-sheet strength
Current ratio ▲+1.640Net debt / EBITDA ▼-1.064Working capital ▲+97593000.000Invested capital ▲+98851000.000Intangibles / Total assets n/a
Employee count
Peer market caps
Congressional trades
No congressional trade data synced.
Recent news
- 2026-09-02 BlackRock Inc. Acquires New Holdings in CeriBell, Inc. $CBLL BlackRock Inc. bought a new position in shares of CeriBell, Inc. (NASDAQ: CBLL) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 1,936,093 shares of the company''s stock, valued at approximately $37,657,000. BlackRock Inc. owned approximately 5.10% of CeriBell as
- 2026-08-27 Bank of America Corp DE Has $5.86 Million Position in CeriBell, Inc. $CBLL Bank of America Corp DE boosted its holdings in CeriBell, Inc. (NASDAQ: CBLL) by 15.3% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 319,837 shares of the company''s stock after acquiring an additional 42,340 shares during the
- 2026-08-12 CeriBell Expands EEG Platform Beyond Seizures With Delirium, Pediatric Push CeriBell NASDAQ: CBLL outlined its plans to expand its brainwave-monitoring platform beyond seizure detection, pointing to new products for delirium, pediatric patients and eventually stroke as it continues to build its hospital customer base.
- 2026-08-11 CeriBell, Inc. (CBLL) Q2 2026 Earnings Call Transcript CeriBell, Inc. (CBLL) Q2 2026 Earnings Call Transcript
- 2026-08-10 Here''s What Key Metrics Tell Us About CeriBell, Inc. (CBLL) Q2 Earnings Although the revenue and EPS for CeriBell, Inc. (CBLL) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
- 2026-08-10 CeriBell, Inc. (CBLL) Reports Q2 Loss, Tops Revenue Estimates CeriBell, Inc. (CBLL) came out with a quarterly loss of $0.51 per share versus the Zacks Consensus Estimate of a loss of $0.45. This compares to a loss of $0.38 per share a year ago.
- 2026-08-10 CeriBell Q2 Earnings Call Highlights CeriBell NASDAQ: CBLL reported second-quarter 2026 revenue growth of 33% as increased utilization at existing hospital accounts and continued customer additions supported results. The company also raised its full-year revenue outlook and outlined plans to commercially launch its delirium-monitoring solution later this year.
- 2026-08-10 Ceribell Receives FDA Clearance for Advanced Epileptiform Abnormality Detection and Artifact Reduction for Its Cloud-Based Portal, Delivering Greater Precision for Critical-Care EEG Review SUNNYVALE, Calif., Aug. 10, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell” or the “Company”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance for two new AI algorithm enhancements integrated directly into its existing cloud-based Neurology Portal: Epileptiform Abnormality Detection and Artifact Reduction.1 These new capabilities expand the clinical utility of the Ceribell Point-of-Care (POC) brain monitoring system, providing neurologists and bedside practitioners with an enhanced toolset for rapid, high-confidence electroencephalogram (EEG) assessment.
- 2026-08-03 Ceribell Secures CMS New Technology Add-On Payment (NTAP) for Breakthrough Point-of-Care Delirium Monitor System Incremental NTAP Reimbursement Stands to Broaden Access to First-of-Its-Kind Dual Seizure and Delirium Monitoring Platform Incremental NTAP Reimbursement Stands to Broaden Access to First-of-Its-Kind Dual Seizure and Delirium Monitoring Platform
- 2026-07-29 Ceribell Expands Board of Directors with Appointments of Thomas West and Sharon O''Keefe SUNNYVALE, Calif., July 29, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced the appointments of Thomas “Tom” West and Sharon O''Keefe to its Board of Directors.